NASDAQ:IMGN   ImmunoGen, Inc
Hi, today we are going to talk about Immunogen and its current landscape.

Immunogen is poised to receive increasing attention from the market after the announcement that it will start new trials based on an FDA advice that a new single-arm study in ovarian cancer could support accelerated approval for Mirvetuximab Soravtansine. We must remember that statistics show that in 2019, about 22,530 women* were expected to be diagnosticated with ovarian cancer, and is expected a mortality of 13,980 women in the same period, which shows the potential growth of this product once hit the market (after the FDA approval), depending on the outcome Immunogen can back to see shining days once more.

Thank you for reading and leave your comments if you like.

To have access to our exclusive contents, join the Traders Heaven today! Link Below.

Disclaimer: All content of Golden Dragon has only educational and informational purposes, and never should be used or take it as financial advice.

*Source: American Cancer Society